4llq - Revision history

OCA at 16:21, 20 September 2023

OCA — Wed, 20 Sep 2023 16:21:09 GMT

←Older revision		Revision as of 16:21, 20 September 2023
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4llq]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LLQ OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4LLQ FirstGlance]. <br>		<table><tr><td colspan='2'>[[4llq]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LLQ OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4LLQ FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=PG6:1-(2-METHOXY-ETHOXY)-2-{2-[2-(2-METHOXY-ETHOXY]-ETHOXY}-ETHANE'>PG6</scene></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 1.42Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=PG6:1-(2-METHOXY-ETHOXY)-2-{2-[2-(2-METHOXY-ETHOXY]-ETHOXY}-ETHANE'>PG6</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4llq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4llq OCA], [https://pdbe.org/4llq PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4llq RCSB], [https://www.ebi.ac.uk/pdbsum/4llq PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4llq ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4llq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4llq OCA], [https://pdbe.org/4llq PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4llq RCSB], [https://www.ebi.ac.uk/pdbsum/4llq PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4llq ProSAT]</span></td></tr>
	</table>		</table>

OCA at 11:09, 14 December 2022

OCA — Wed, 14 Dec 2022 11:09:36 GMT

←Older revision		Revision as of 11:09, 14 December 2022
Line 1:		Line 1:

	==Structure of redesigned IgG1 first constant and lambda domains (CH1:Clambda constant redesign 2 beta, CRD2b) at 1.42A==		==Structure of redesigned IgG1 first constant and lambda domains (CH1:Clambda constant redesign 2 beta, CRD2b) at 1.42A==
-	<StructureSection load='4llq' size='340' side='right' caption='[[4llq]], [[Resolution\|resolution]] 1.42Å' scene=''>	+	<StructureSection load='4llq' size='340' side='right'caption='[[4llq]], [[Resolution\|resolution]] 1.42Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4llq]] is a 2 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LLQ OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4LLQ FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4llq]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LLQ OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4LLQ FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=PG6:1-(2-METHOXY-ETHOXY)-2-{2-[2-(2-METHOXY-ETHOXY]-ETHOXY}-ETHANE'>PG6</scene>~~</td></tr>~~	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=PG6:1-(2-METHOXY-ETHOXY)-2-{2-[2-(2-METHOXY-ETHOXY]-ETHOXY}-ETHANE'>PG6</scene></td></tr>
-	~~<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4lld\|4lld]], [[4llm\|4llm]], [[4llu\|4llu]], [[4llw\|4llw]], [[4lly\|4lly]]</td></tr>~~	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4llq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4llq OCA], [https://pdbe.org/4llq PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4llq RCSB], [https://www.ebi.ac.uk/pdbsum/4llq PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4llq ProSAT]</span></td></tr>
-	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">DKFZp686G11190 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN]), IGL@ ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>	+
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4llq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4llq OCA], [~~http~~://pdbe.org/4llq PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=4llq RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/4llq PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=4llq ProSAT]</span></td></tr>	+
	</table>		</table>
		+	== Disease ==
		+	[https://www.uniprot.org/uniprot/IGHG1_HUMAN IGHG1_HUMAN] Defects in IGHG1 are a cause of multiple myeloma (MM) [MIM:[https://omim.org/entry/254500 254500]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving IGHG1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus. Translocation t(11;14)(q13;q32) with CCND1; translocation t(4;14)(p16.3;q32.3) with FGFR3; translocation t(6;14)(p25;q32) with IRF4.
		+	== Function ==
		+	[https://www.uniprot.org/uniprot/IGHG1_HUMAN IGHG1_HUMAN]
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 22:		Line 24:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
-	[[Category: Atwell, S]]	+	[[Category: Large Structures]]
-	[[Category: Chamberlain~~, A K~~]]	+	[[Category: Atwell S]]
-	[[Category: Demarest~~, S J~~]]	+	[[Category: Chamberlain AK]]
-	[[Category: Guntas, G]]	+	[[Category: Demarest SJ]]
-	[[Category: Hansen-Estruch, C]]	+	[[Category: Guntas G]]
-	[[Category: Ho, C]]	+	[[Category: Hansen-Estruch C]]
-	[[Category: Huang, F]]	+	[[Category: Ho C]]
-	[[Category: Kuhlman, B]]	+	[[Category: Huang F]]
-	[[Category: Leaver-Fay, A]]	+	[[Category: Kuhlman B]]
-	[[Category: Lewis~~, S M~~]]	+	[[Category: Leaver-Fay A]]
-	[[Category: Pustilnik, A]]	+	[[Category: Lewis SM]]
-	[[Category: Sereno, A]]	+	[[Category: Pustilnik A]]
-	[[Category: Smith~~, E M~~]]	+	[[Category: Sereno A]]
-	[[Category: Truhlar~~, S M~~]]	+	[[Category: Smith EM]]
-	[[Category: Wu, X]]	+	[[Category: Truhlar SM]]
-	~~[[Category: Igg domain redesign]]~~	+	[[Category: Wu X]]
-	~~[[Category: Immune system~~]]	+

OCA at 15:04, 11 August 2016

OCA — Thu, 11 Aug 2016 15:04:30 GMT

←Older revision		Revision as of 15:04, 11 August 2016
Line 1:		Line 1:
		+
	==Structure of redesigned IgG1 first constant and lambda domains (CH1:Clambda constant redesign 2 beta, CRD2b) at 1.42A==		==Structure of redesigned IgG1 first constant and lambda domains (CH1:Clambda constant redesign 2 beta, CRD2b) at 1.42A==
	<StructureSection load='4llq' size='340' side='right' caption='[[4llq]], [[Resolution\|resolution]] 1.42Å' scene=''>		<StructureSection load='4llq' size='340' side='right' caption='[[4llq]], [[Resolution\|resolution]] 1.42Å' scene=''>
Line 6:		Line 7:
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4lld\|4lld]], [[4llm\|4llm]], [[4llu\|4llu]], [[4llw\|4llw]], [[4lly\|4lly]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4lld\|4lld]], [[4llm\|4llm]], [[4llu\|4llu]], [[4llw\|4llw]], [[4lly\|4lly]]</td></tr>
	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">DKFZp686G11190 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN]), IGL@ ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>		<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">DKFZp686G11190 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN]), IGL@ ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4llq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4llq OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4llq RCSB], [http://www.ebi.ac.uk/pdbsum/4llq PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4llq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4llq OCA], [http://pdbe.org/4llq PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4llq RCSB], [http://www.ebi.ac.uk/pdbsum/4llq PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4llq ProSAT]</span></td></tr>
	</table>		</table>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
Line 16:		Line 17:
	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	</div>		</div>
		+	<div class="pdbe-citations 4llq" style="background-color:#fffaf0;"></div>
	== References ==		== References ==
	<references/>		<references/>

OCA at 09:12, 5 January 2015

OCA — Mon, 05 Jan 2015 09:12:55 GMT

←Older revision		Revision as of 09:12, 5 January 2015
Line 1:		Line 1:
-	~~{{STRUCTURE_4llq\| PDB=4llq \| SCENE= }}~~	+	==Structure of redesigned IgG1 first constant and lambda domains (CH1:Clambda constant redesign 2 beta, CRD2b) at 1.42A==
-	===Structure of redesigned IgG1 first constant and lambda domains (CH1:Clambda constant redesign 2 beta, CRD2b) at 1.42A===	+	<StructureSection load='4llq' size='340' side='right' caption='[[4llq]], [[Resolution\|resolution]] 1.42Å' scene=''>
-	{~~{ABSTRACT_PUBMED_24463572}~~}	+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[4llq]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LLQ OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4LLQ FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=PG6:1-(2-METHOXY-ETHOXY)-2-{2-[2-(2-METHOXY-ETHOXY]-ETHOXY}-ETHANE'>PG6</scene></td></tr>
		+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4lld\|4lld]], [[4llm\|4llm]], [[4llu\|4llu]], [[4llw\|4llw]], [[4lly\|4lly]]</td></tr>
		+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">DKFZp686G11190 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN]), IGL@ ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4llq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4llq OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4llq RCSB], [http://www.ebi.ac.uk/pdbsum/4llq PDBsum]</span></td></tr>
		+	</table>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Robust generation of IgG bispecific antibodies has been a long-standing challenge. Existing methods require extensive engineering of each individual antibody, discovery of common light chains, or complex and laborious biochemical processing. Here we combine computational and rational design approaches with experimental structural validation to generate antibody heavy and light chains with orthogonal Fab interfaces. Parental monoclonal antibodies incorporating these interfaces, when simultaneously co-expressed, assemble into bispecific IgG with improved heavy chain-light chain pairing. Bispecific IgGs generated with this approach exhibit pharmacokinetic and other desirable properties of native IgG, but bind target antigens monovalently. As such, these bispecific reagents may be useful in many biotechnological applications.

-	~~==About this Structure==~~	+	Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface.,Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C, Hansen-Estruch C, Chamberlain AK, Truhlar SM, Conner EM, Atwell S, Kuhlman B, Demarest SJ Nat Biotechnol. 2014 Feb;32(2):191-8. doi: 10.1038/nbt.2797. Epub 2014 Jan 26. PMID:24463572<ref>PMID:24463572</ref>
-	~~[[4llq]] is a 2 chain~~ structure. ~~Full crystallographic information is available from [http~~:/~~/oca~~.~~weizmann~~.ac.il/~~oca-bin/ocashort?id=4LLQ OCA].~~	+

-	==~~Reference~~==	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	~~<ref group="xtra">PMID:024463572</ref>~~<references ~~group="xtra"~~/><~~references~~/>	+	</div>
-	[[Category: Atwell, S.]]	+	== References ==
-	[[Category: Chamberlain, A K.]]	+	<references/>
-	[[Category: Demarest, S J.]]	+	__TOC__
-	[[Category: Guntas, G.]]	+	</StructureSection>
-	[[Category: Hansen-Estruch, C.]]	+	[[Category: Human]]
-	[[Category: Ho, C.]]	+	[[Category: Atwell, S]]
-	[[Category: Huang, F.]]	+	[[Category: Chamberlain, A K]]
-	[[Category: Kuhlman, B.]]	+	[[Category: Demarest, S J]]
-	[[Category: Leaver-Fay, A.]]	+	[[Category: Guntas, G]]
-	[[Category: Lewis, S M.]]	+	[[Category: Hansen-Estruch, C]]
-	[[Category: Pustilnik, A.]]	+	[[Category: Ho, C]]
-	[[Category: Sereno, A.]]	+	[[Category: Huang, F]]
-	[[Category: Smith, E M.]]	+	[[Category: Kuhlman, B]]
-	[[Category: Truhlar, S M.]]	+	[[Category: Leaver-Fay, A]]
-	[[Category: Wu, X.]]	+	[[Category: Lewis, S M]]
		+	[[Category: Pustilnik, A]]
		+	[[Category: Sereno, A]]
		+	[[Category: Smith, E M]]
		+	[[Category: Truhlar, S M]]
		+	[[Category: Wu, X]]
	[[Category: Igg domain redesign]]		[[Category: Igg domain redesign]]
	[[Category: Immune system]]		[[Category: Immune system]]

OCA at 03:29, 13 February 2014

OCA — Thu, 13 Feb 2014 03:29:14 GMT

←Older revision		Revision as of 03:29, 13 February 2014
Line 1:		Line 1:
	{{STRUCTURE_4llq\| PDB=4llq \| SCENE= }}		{{STRUCTURE_4llq\| PDB=4llq \| SCENE= }}
	===Structure of redesigned IgG1 first constant and lambda domains (CH1:Clambda constant redesign 2 beta, CRD2b) at 1.42A===		===Structure of redesigned IgG1 first constant and lambda domains (CH1:Clambda constant redesign 2 beta, CRD2b) at 1.42A===
		+	{{ABSTRACT_PUBMED_24463572}}

	==About this Structure==		==About this Structure==
	[[4llq]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LLQ OCA].		[[4llq]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LLQ OCA].
		+
		+	==Reference==
		+	<ref group="xtra">PMID:024463572</ref><references group="xtra"/><references/>
	[[Category: Atwell, S.]]		[[Category: Atwell, S.]]
	[[Category: Chamberlain, A K.]]		[[Category: Chamberlain, A K.]]

OCA at 07:48, 29 January 2014

OCA — Wed, 29 Jan 2014 07:48:51 GMT

←Older revision		Revision as of 07:48, 29 January 2014
Line 1:		Line 1:
-	~~'''Unreleased structure'''~~	+	{{STRUCTURE_4llq\| PDB=4llq \| SCENE= }}
		+	===Structure of redesigned IgG1 first constant and lambda domains (CH1:Clambda constant redesign 2 beta, CRD2b) at 1.42A===

-	~~The entry~~ 4llq is ~~ON HOLD until Paper Publication~~	+	==About this Structure==
-		+	[[4llq]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LLQ OCA].
-	~~Authors~~: ~~Pustilnik~~, A.~~, Lewis~~, S.M., ~~Wu, X~~., ~~Sereno, A~~., Huang, F., ~~Guntas, G~~., Leaver-Fay, A., ~~Smith, E.~~M., ~~Ho, C~~.~~, Hansen-Estruch, C., Chamberlain~~, A.K., Truhlar, S.M., ~~Kuhlman, B., Demarest, S.J., Atwell, S~~.	+	[[Category: Atwell, S.]]
-		+	[[Category: Chamberlain, A K.]]
-	~~Description~~: ~~Structure of redesigned IgG1 first constant and lambda domains (CH1:Clambda constant redesign 2 beta, CRD2b) at 1.42A~~	+	[[Category: Demarest, S J.]]
		+	[[Category: Guntas, G.]]
		+	[[Category: Hansen-Estruch, C.]]
		+	[[Category: Ho, C.]]
		+	[[Category: Huang, F.]]
		+	[[Category: Kuhlman, B.]]
		+	[[Category: Leaver-Fay, A.]]
		+	[[Category: Lewis, S M.]]
		+	[[Category: Pustilnik, A.]]
		+	[[Category: Sereno, A.]]
		+	[[Category: Smith, E M.]]
		+	[[Category: Truhlar, S M.]]
		+	[[Category: Wu, X.]]
		+	[[Category: Igg domain redesign]]
		+	[[Category: Immune system]]

OCA at 20:11, 7 August 2013

OCA — Wed, 07 Aug 2013 20:11:24 GMT

←Older revision		Revision as of 20:11, 7 August 2013
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 4llq is ON HOLD	+	The entry 4llq is ON HOLD until Paper Publication

	Authors: Pustilnik, A., Lewis, S.M., Wu, X., Sereno, A., Huang, F., Guntas, G., Leaver-Fay, A., Smith, E.M., Ho, C., Hansen-Estruch, C., Chamberlain, A.K., Truhlar, S.M., Kuhlman, B., Demarest, S.J., Atwell, S.		Authors: Pustilnik, A., Lewis, S.M., Wu, X., Sereno, A., Huang, F., Guntas, G., Leaver-Fay, A., Smith, E.M., Ho, C., Hansen-Estruch, C., Chamberlain, A.K., Truhlar, S.M., Kuhlman, B., Demarest, S.J., Atwell, S.

	Description: Structure of redesigned IgG1 first constant and lambda domains (CH1:Clambda constant redesign 2 beta, CRD2b) at 1.42A		Description: Structure of redesigned IgG1 first constant and lambda domains (CH1:Clambda constant redesign 2 beta, CRD2b) at 1.42A

OCA: Protected "4llq" [edit=sysop:move=sysop]

OCA — Thu, 18 Jul 2013 04:47:58 GMT

Protected "4llq" [edit=sysop:move=sysop]

←Older revision

Revision as of 04:47, 18 July 2013

OCA: New page: '''Unreleased structure''' The entry 4llq is ON HOLD Authors: Pustilnik, A., Lewis, S.M., Wu, X., Sereno, A., Huang, F., Guntas, G., Leaver-Fay, A., Smith, E.M., Ho, C., Hansen-Estruch,...

OCA — Thu, 18 Jul 2013 04:47:57 GMT

New page: '''Unreleased structure''' The entry 4llq is ON HOLD Authors: Pustilnik, A., Lewis, S.M., Wu, X., Sereno, A., Huang, F., Guntas, G., Leaver-Fay, A., Smith, E.M., Ho, C., Hansen-Estruch,...

New page

'''Unreleased structure'''

The entry 4llq is ON HOLD

Authors: Pustilnik, A., Lewis, S.M., Wu, X., Sereno, A., Huang, F., Guntas, G., Leaver-Fay, A., Smith, E.M., Ho, C., Hansen-Estruch, C., Chamberlain, A.K., Truhlar, S.M., Kuhlman, B., Demarest, S.J., Atwell, S.

Description: Structure of redesigned IgG1 first constant and lambda domains (CH1:Clambda constant redesign 2 beta, CRD2b) at 1.42A